RNAZ
TransCode Therapeutics, Inc.Healthcare · $2M market cap
Verdict
We can't put a fair value on RNAZ right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow RNAZ
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 9, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Other filings
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works